GMN
0.002
100%
TOU
0.03
-25%
H2G
0.011
83.3%
AUK
0.004
-20%
EVR
0.006
50%
BCB
0.004
-20%
HE8
0.012
33.3%
EV1
0.013
-18.8%
OVT
0.005
25%
EPM
0.005
-16.7%
RR1
0.01
25%
WSR
0.005
-16.7%
AYT
0.006
20%
AZL
0.006
-14.3%
CMP
0.3
17.6%
IXR
0.006
-14.3%
SWP
0.17
17.2%
KGD
0.006
-14.3%
BDG
0.055
17%
GLA
0.007
-12.5%
MGU
0.007
16.7%
1AD
0.009
-10%
CPO
0.016
14.3%
JGH
0.028
-9.7%
PLY
0.227
13.5%
NVU
0.047
-9.6%
LDR
0.13
13%
ELT
0.057
-9.5%
CRS
0.063
12.5%
RNT
0.019
-9.5%
NAG
0.018
12.5%
KAI
0.02
-9.1%
PSC
0.145
11.5%
MDR
0.1
-9.1%
UVA
0.089
11.3%
PER
0.01
-9.1%
AEV
0.01
11.1%
SMX
0.05
-9.1%
HTM
0.25
11.1%
APC
0.011
-8.3%

PharmAust Limited (ASX:PAA): Developing new treatments for neurodegenerative diseases

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, PharmAust’s (ASX:PAA) Managing Director Dr Michael Thurn speaks with The Stock Network’s Lel Smits about:

🧬 A re-prioritised commercialisation strategy: PharmAust focus on neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s disease
🧬 Monepantel gets US FDA Orphan Drug Designation for treatment of ALS:
Next steps following PharmAust’s Monepantel recently granted Orphan Drug Designation for the treatment of ALS by the US FDA

Watch the full interview ⚡️ https://youtu.be/VJkvSG3bkrA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved